Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735248 | 0.89 | ADORA3 (0.43) | ADORA3PRMT5WDR77TYMP | |
| SCHEMBL733590 | 0.82 | P2RY6 (0.36) | — | |
| SCHEMBL733396 | 0.79 | ADORA3 (0.41) | ADORA3PRMT5WDR77 | |
| SCHEMBL736838 | 0.78 | PRMT5 (0.38) | ADORA3PRMT5WDR77 | |
| SCHEMBL5859661 | 0.70 | P2RX3 (0.43) | — | |
| SCHEMBL888000 | 0.69 | ADORA3 (0.43) | ADORA3 | |
| SCHEMBL733926 | 0.69 | POLB (0.38) | — | |
| SCHEMBL733418 | 0.69 | POLB (0.32) | — | |
| SCHEMBL888001 | 0.68 | ADORA3 (0.45) | ADORA3 | |
| SCHEMBL734847 | 0.68 | P2RY12 (0.31) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | ADORA3 659/4885PRMT5 1764/4885WDR77 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.